GSK Regulatory Update: Avodart
Links shared publicly online about this topic.
- 1,581total visits
GSK Regulatory Update: Avodart
View full resource at us.gsk.com
Tags: Cancer, Cancer Prevention, Prostate Cancer, Prostate, Benign Prostatic Hypertrophy Medication, Men's Health, Avodart, GlaxoSmithKline
Most Recently Shared on November 23, 2009 at 3:11 pm By:
GSK withdraws sNDA for Avodart for prostate cancer prevention http://ow.ly/ET4W
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine
us.gsk.com — “Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine” View full resource at us.gsk.com
Most Recently Shared on December 1, 2011 at 3:46 pm By:
eyeonfda Pharma and Health Lawyer
GSK submits additional info to FDA for candidate meningococcal and Hib combination vaccine http://t.co/7O2I9g7m
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
us.gsk.com — “Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia” View full resource at us.gsk.com
Most Recently Shared on August 10, 2011 at 1:10 pm By:
eyeonfda Pharma and Health Lawyer
GSK and XenoPort submit supplemental NDA to #FDA for Horizant™ in postherpetic #neuralgia http://ow.ly/5ZEGt
GlaxoSmithKline European Regulatory Update on Pandemrix - Drugs.com MedNews
drugs.com — “Issued Thursday 21 July 2011, London UK GlaxoSmithKline (GSK) announced today that the European Medicines Agency s (EMA) Committee for Medicinal Products for Hu” View full resource at drugs.com
Most Recently Shared on July 22, 2011 at 2:04 pm By:
Drugs and Devices OW OW Health
GlaxoSmithKline European Regulatory Update on Pandemrix: Issued: Thursday 21 July 2011, London UK GlaxoSmi... http://bit.ly/nb2qbq #drug
GlaxoSmithKline European regulatory update on Pandemrix™
gsk.com — “GlaxoSmithKline European regulatory update on Pandemrix™” View full resource at gsk.com
Most Recently Shared on July 21, 2011 at 9:09 pm By:
GlaxoSmithKline European regulatory update on Pandemrixâ„¢: GlaxoSmithKline (GSK) announced today that the Europ... http://bit.ly/pZzs2y
Regulatory update -- GSK and Valeant respond to FDA on ezogabine
us.gsk.com — “Regulatory update -- GSK and Valeant respond to FDA on ezogabine” View full resource at us.gsk.com
Most Recently Shared on April 18, 2011 at 1:16 pm By:
eyeonfda Pharma and Health Lawyer
GSK and Valeant Pharmaceuticals submit response to FDA CRL for ezogabine NDA http://ow.ly/4CraX
GlaxoSmithKline drops Avodart for prostate cancer risk reduction - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “UK pharma giant GlaxoSmithKline (LSE: GSK) says that it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer. The company will withdraw applications from regulatory review where procedures are on” View full resource at thepharmaletter.com
Most Recently Shared on March 24, 2011 at 5:35 pm By:
GlaxoSmithKline drops Avodart for prostate cancer risk reduction http://bit.ly/gRCa25
GSK scraps plans to market prostate-cancer drug | The Associated Press | News | Washington Examiner
washingtonexaminer.com — “Drug giant GlaxoSmithKline PLC says it will no longer pursue global regulatory approval to market its Avodart drug to treat prostate cancer following negative feedback from American and Swedish regulators. Avodart is approved in more than 90 countries to treat an enlarged prostate.” View full resource at washingtonexaminer.com
Most Recently Shared on March 23, 2011 at 11:47 pm By:
GSK scraps plans to market prostate-cancer drug | The Associated ... http://bit.ly/eyOgBn
GSK scraps plans to market prostate-cancer drug
health.yahoo.net — “Drug giant GlaxoSmithKline PLC says it will no longer pursue global regulatory approval to market its Avodart drug to treat prostate cancer following negative feedback from American and Swedish regulators.” View full resource at health.yahoo.net
Most Recently Shared on March 23, 2011 at 4:40 pm By:
GSK scraps plans to market prostate-cancer drug http://bit.ly/hQd6cL
Regulatory update: Nimenrix® (MenACWY vaccine)
gsk.com — “GlaxoSmithKline (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its candidate conjugate meningitis vaccine, Nimenrix®,” View full resource at gsk.com
Most Recently Shared on March 2, 2011 at 2:49 pm By:
eyeonfda Pharma and Health Lawyer
GSK submits Marketing Authorisation Application (MAA) to EMA for candidate conjugate meningitis vaccine, Nimenrix® - http://ow.ly/46mkF
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction
medicalnewstoday.com — “GlaxoSmithKline (NYSE: GSK) announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (s” View full resource at medicalnewstoday.com
Most Recently Shared on December 2, 2010 at 3:37 pm By:
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction GlaxoSmithKline (NYSE: GSK) announced the.. http://dld.bz/8Wrf
GSK Regulatory Update On Avandia Following EMA And FDA Reviews
medicalnewstoday.com — “GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), e” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 8:05 pm By:
MNT Drug Approvals Health News
GSK Regulatory Update On Avandia Following EMA And FDA Reviews http://mnt.to/3Khv #regulatory
GSK EU regulatory update on Avandia (rosiglitazone)
gsk.com — “GSK EU regulatory update on Avandia (rosiglitazone)” View full resource at gsk.com
Most Recently Shared on July 9, 2010 at 2:14 pm By:
eyeonfda Pharma and Health Lawyer
EMA sets meeting to review benefit/risk profile of Avandia - http://ow.ly/29dIy
Regulatory update - Benlysta (belimumab)
gsk.com — “Regulatory update - Benlysta (belimumab)” View full resource at gsk.com
Most Recently Shared on June 7, 2010 at 1:11 pm By:
eyeonfda Pharma and Health Lawyer
GSK files MAA 2 EMA 4 Benlysta (belimumab) 4 reducing disease activity in lupus patients receiving standardtherapy http://ow.ly/1V1Fb
GSK Regulatory Update Avodart (dutasteride)
medicalnewstoday.com — “GlaxoSmithKline (NYSE: GSK) announced that it has re-submitted the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for prostate cancer risk reduction among men at increase” View full resource at medicalnewstoday.com
Most Recently Shared on March 30, 2010 at 2:07 pm By:
GSK Regulatory Update Avodart (dutasteride) http://mnt.to/3zBF #prostate
Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine)
gsk.com — “not named” View full resource at gsk.com
Most Recently Shared on March 26, 2010 at 3:23 pm By:
eyeonfda Pharma and Health Lawyer
Updated GSK statement on EU regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine) - http://ow.ly/1rgbR
Advertisement
